The medium term support area around 60.5 CHF should allow Implenia AG shares to re-establish an upward trend in the short term. Investors have an opportunity to buy the stock and target the CHF 69.4.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at CHF 62.6 CHF in weekly data.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.2 for the 2017 fiscal year.
The company is one of the best yield companies with high dividend expectations.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 37.44 times its estimated earnings per share for the ongoing year.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
For the past year, analysts have significantly revised downwards their profit estimates.
The underlying tendency is negative on the weekly chart below the resistance at 69.7 CHF
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.